长春高新(000661) - 2017 Q3 - 季度财报

Financial Performance - Total assets increased to ¥7,418,413,664.45, a rise of 19.58% compared to the previous year[8] - Net profit attributable to shareholders reached ¥202,962,852.51, reflecting a growth of 23.18% year-on-year[8] - Operating revenue for the period was ¥1,047,493,649.80, representing a 14.31% increase compared to the same period last year[8] - Basic earnings per share were ¥1.19, up 22.68% from the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥195,147,538.01, an increase of 24.06% year-on-year[8] - The company's net profit attributable to shareholders increased by 28.31% year-on-year[16] Cash Flow and Investments - Net cash flow from operating activities decreased by 42.78% to ¥69,055,423.91 year-to-date[8] - Cash received from operating activities increased by 272,142,074.15 CNY, a growth of 246.08% due to the recovery of land guarantee deposits[23] - Investment income surged by 28,346,988.15 CNY, a growth of 456.46% due to increased returns from financial products[23] - The company reported a decrease in long-term borrowings by 5,500,000.00 CNY, a reduction of 71.71% due to new borrowings in the pharmaceutical segment[20] Shareholder Information - The company reported a total of 14,133 common shareholders at the end of the reporting period[12] - The largest shareholder, Changchun Gaoxin Chaoda Investment Co., Ltd., holds 22.36% of the shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] Segment Performance - The pharmaceutical segment achieved a revenue growth of 55.31% and a net profit growth of 65.97% during the reporting period[16] - Accounts receivable increased by 308,578,312.89 CNY, a growth of 69.13% due to revenue growth in the pharmaceutical segment[16] - Sales expenses rose by 437,396,464.18 CNY, an increase of 65.66% attributed to higher revenue in the pharmaceutical sector[23] Assets and Expenses - Inventory rose by 1,431,532,004.27 CNY, a significant increase of 211.65% due to ongoing construction projects in the real estate sector[17] - Research and development expenses increased by 40,522,409.89 CNY, a growth of 43.40% driven by increased investment in new drug development[18] - Other non-current assets increased by 49,019,329.02 CNY, a growth of 79.63% due to prepayments for new factory construction and equipment[18] - The weighted average return on equity was 4.89%, a decrease of 0.45% compared to the previous year[8]